Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54257099 in Healthy Subjects and Subjects with Chronic Hepatitis C
NCT02510248Phase 1Terminated
- Sponsor
- Alios BioPharma
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of AL-704 in hepatitis C (HCV) (3 arms), sponsored by Alios BioPharma. Primary endpoint: Number and frequency of treatment emergent adverse events up to 21 days. Started Jul 2015; status: terminated.
02
Drugs
AL-704
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02510248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510248.